The Journey of Buprenorphine

Buprenorphine has essentially zero oral bioavailability (<5%)
due to extensive first-pass hepatic metabolism (CYP3A4 N-dealkylation). This complete first-pass
extraction necessitates non-oral delivery routes. Sublingual bioavailability is approximately 30-50%,
as the lipophilic drug (logP ~4.98) rapidly crosses the sublingual mucosa into the venous drainage
that bypasses first-pass. Buccal film (Belbuca) achieves similar bioavailability. Transdermal patch
formulations (Butrans) provide sustained systemic delivery with bioavailability of approximately
15%, suitable for chronic pain management. Subcutaneous and intramuscular injection achieve near-
complete bioavailability for acute pain applications. Extended-release subcutaneous buprenorphine
depot formulations (Sublocade, Brixia) provide monthly dosing by forming a solid depot of
buprenorphine-ATRIGEL polymer at the injection site that slowly releases drug over 4 weeks,
dramatically simplifying opioid use disorder treatment.

Buprenorphine is highly lipophilic (logP ~4.98) and distributes
extensively throughout body tissues with a volume of distribution of approximately 188-335 L/kg —
among the largest Vd values of any drug, reflecting profound tissue sequestration particularly in
the CNS. Plasma protein binding is approximately 96%, primarily to globulins including beta and
gamma globulins. High lipophilicity enables rapid CNS penetration (within minutes of IV or sublingual
administration). The drug undergoes extensive enterohepatic recirculation: excreted glucuronide
conjugates are hydrolyzed by gut bacteria and reabsorbed, contributing to the drug's very long
duration of action and slow decline in plasma concentrations. Buprenorphine crosses the placenta
and is present in breast milk; neonates of mothers on buprenorphine maintenance therapy
may exhibit neonatal opioid withdrawal syndrome (NOWS), managed with morphine or buprenorphine.

Buprenorphine is a partial agonist at the mu-opioid receptor (MOR,
OPRM1) and an antagonist at the kappa-opioid receptor (KOR). At MOR, buprenorphine binds with
extraordinarily high affinity (Ki ~0.2-0.5 nM — 25-100 times higher than morphine) and very slow
receptor dissociation (half-life of receptor-drug complex approximately 166 minutes vs. ~5 minutes
for morphine). Despite this near-irreversible receptor occupancy, buprenorphine is only a partial
agonist — it activates Gi signaling (adenylyl cyclase inhibition, GIRK opening, calcium channel
inhibition) to a submaximal extent even at full receptor occupancy. The partial agonism creates
a ceiling on dose-response: above a certain dose, increasing buprenorphine produces no additional
respiratory depression (the ceiling effect) — fundamentally distinguishing it from full agonists
(morphine, fentanyl, methadone). High MOR occupancy blocks access of other opioids, explaining
its use to block opioid craving and prevent illicit opioid highs. Naloxone is added to sublingual
formulations (Suboxone = buprenorphine/naloxone 4:1) to deter injection misuse.

Buprenorphine is metabolized primarily in the liver by CYP3A4
via N-dealkylation to norbuprenorphine — an active metabolite with full agonist activity at MOR
and KOR. Norbuprenorphine (approximately 20-40% of parent concentrations at steady state) has lower
CNS penetration than buprenorphine due to P-glycoprotein efflux at the blood-brain barrier,
potentially explaining why it produces less analgesia relative to its in vitro potency. Both
buprenorphine and norbuprenorphine undergo glucuronidation by UGT1A1 and UGT2B7 to form
buprenorphine-3-glucuronide (B3G, inactive) and norbuprenorphine-3-glucuronide (NB3G, minor
activity). B3G is the predominant circulating conjugate. CYP3A4 inhibitors increase buprenorphine
and norbuprenorphine exposure; inducers reduce them. QTc prolongation risk at high doses has been
reported for parenteral formulations.

Buprenorphine and its metabolites are excreted primarily in feces
(approximately 68-72%) via biliary elimination of glucuronide conjugates, with approximately 27-30%
in urine. The prolonged terminal half-life of buprenorphine ranges from 24-42 hours for sublingual
formulations, extending to approximately 43 hours for the buccal film. The extended duration of
action (compared to the plasma half-life) reflects both the large volume of distribution causing
slow tissue release and the slow MOR dissociation kinetics. Monthly subcutaneous depot formulations
have a terminal half-life of approximately 43-60 days after the last injection — plasma concentrations
remain detectable and pharmacologically active for months after the depot is fully absorbed.
Renal impairment does not significantly alter buprenorphine pharmacokinetics. Hepatic impairment
reduces first-pass metabolism (oral route only) and may increase systemic exposure.

Buprenorphine/naloxone (Suboxone) is the preferred pharmacotherapy
for opioid use disorder (OUD) in outpatient settings, superior to placebo and comparable to
methadone in randomized trials for retention in treatment and illicit opioid use reduction.
Its safety advantage over methadone (less QTc prolongation, no daily clinic dispensing requirement)
and over naltrexone (no requirement for prior detoxification) drives its widespread use. In acute
and chronic pain, buprenorphine's long duration (transdermal patch provides 7-day coverage) and
ceiling effect make it attractive for patients at high risk of opioid overdose. Naloxone reverses
buprenorphine respiratory depression but requires higher doses and may need repeat administration
given buprenorphine's tight receptor binding. Opioid withdrawal syndrome upon abrupt discontinuation
is generally milder than full agonists due to partial agonism.